BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.39
- Market cap
- ₹11.76 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 42.0×Sector 45.9×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Other debt & borrowing announcements
All →Neogen Chemicals Debt & Borrowing: ₹500 Cr
Neogen Chemicals approved in-principle a Rs 500 Crore corporate guarantee for Neogen Morita's borrowings, subject to shareholder approval. The company reports no adverse impact.
- Value
- ₹500.0 Cr
Satin Creditcare Network Debt & Borrowing: ₹1.83 Cr
Satin Creditcare paid Rs.1.83 Crore quarterly interest on its 10.40% April 2027 NCDs on 31 October 2026. The payment fulfils an existing debt obligation.
- Value
- ₹1.83 Cr
AAA Technologies Debt & Borrowing: ₹6 Cr
AAA Technologies approved an inter-corporate loan of up to Rs.6 Crore to Transaction Solutions International at 12% interest. Repayable on demand; share-pledge security is proposed.
- Value
- ₹6.00 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹12.5 Cr
Spandana Sphoorty partially redeemed Rs 12.50 Crore of its listed secured NCDs on 31 October 2026 by face-value redemption. Rs 200 Crore remains outstanding.
- Value
- ₹12.50 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹2.71 Cr
Spandana Sphoorty paid monthly interest of Rs 2.71 Crore across two listed secured NCD series on 30 October 2026, on time. Series-wise amounts were Rs 2.01 Crore and Rs 0.70 Crore.
- Value
- ₹2.71 Cr
Industrial Investment Trust Debt & Borrowing: ₹200 Cr
Industrial Investment Trust's board approved borrowing up to Rs. 200 Crore from banks, NBFCs and other lenders, within the Rs. 1,000 Crore shareholder limit. The enabling approval names no specific lender yet.
- Value
- ₹200.0 Cr